UnknownPhase 2NCT03700229
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
Studying Acquired hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking Union Medical College Hospital
- Principal Investigator
- Tienan ZhuPeking Union Medical College Hospital
- Intervention
- Bortezomib(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (1)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03700229 on ClinicalTrials.govOther trials for Acquired hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06550882A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South KoreaTakeda
- RECRUITINGNCT06461533A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia ATakeda
- ACTIVE NOT RECRUITINGPHASE2NCT05345197Emicizumab in Patients With Acquired Hemophilia AUniversity of Washington